CancerDrs

Prostate Cancer clinical trials in Rhode Island

8 actively recruiting prostate cancer trials at 1 site across Rhode Island.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Network

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
  • Miriam Hospital — Providence, Rhode Island
Phase 3 Recruiting Industry

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…

Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Rhode Island:
  • Research Site — Providence, Rhode Island
Phase 1, Phase 2 Recruiting Industry

First-in-Human Study to Evaluate AZD8359 STEAP2 TCE in Participants With Prostate Cancer

This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD8359. The study is split into different modules which will look at AZD8359 …

Sponsor: AstraZeneca
NCT ID: NCT07529717
Sites in Rhode Island:
  • Research Site — Providence, Rhode Island
Phase 1 Recruiting Industry

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant p…

Sponsor: Janux Therapeutics
NCT ID: NCT05519449
Sites in Rhode Island:
  • Rhode Island Hospital — Providence, Rhode Island
Phase 1 Recruiting Industry

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer

Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and efficacy of ABBV-969 as a monotherapy. …

Sponsor: AbbVie
NCT ID: NCT06318273
Sites in Rhode Island:
  • Lifespan Cancer Institute at Rhode Island Hospital /ID# 261687 — Providence, Rhode Island
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Rhode Island:
  • Providence Veterans Administration Hospital — Providence, Rhode Island
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Rhode Island:
  • Massive Bio SYNERGY-AI site — Providence, Rhode Island

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15